Last updated on August 2019

A Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 Oral Treatment in Adults with Essential Tremor (cadence-1)


Brief description of study

This is an open-label study designed to evaluate the safety, tolerability and efficacy of CAD-1883, a positive allosteric modulator of the SK channel, administered twice daily orally to adult patients with essential tremor (ET).

Patients with the diagnosis of ET based on the Movement Disorder Society (MDS) criteria with a documented severity of tremor based on the clinician-administered TETRAS Performance Subscale are eligible to be enrolled in the study.

 

Clinical Study Identifier: TX222122

Find a site near you

Start Over

Quest Research Institute

Located in: Farmington Hills, MI USA
  Connect »

Woodland Research Northwest

Located in: Rogers, AR USA
  Connect »

St. Louis Clinical Trials

Located in: Saint Louis, MO USA
  Connect »

Pinnacle Research

Located in: Anniston, AL USA
  Connect »

MD Clinical

Located in: Hallandale Beach, FL USA
  Connect »

Pacific Research Network

Located in: San Diego, CA USA
  Connect »